Research graph
References from Reduction in Rheumatoid Factor and Matrix Metalloproteinase-3 With Successful Glucocorticoid Withdrawal After Initiation of Pemafibrate in a Patient With Rheumatoid Arthritis and Hypertriglyceridemia: A Case Report. Local targets link to admitted publications; unresolved targets remain external evidence.
Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors
10.1007/s00011-019-01231-1 · 2019 · External reference
NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction
10.1186/ar300 · 2001 · External reference
The pathogenesis of rheumatoid arthritis
10.1056/nejmra1004965 · 2011 · External reference
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
10.1136/ard.2007.084459 · 2009 · External reference
Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values
10.1136/ard.2006.054205 · 2007 · External reference
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
10.1002/art.27584 · 2010 · External reference
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
10.1136/ard.2010.138461 · 2010 · External reference
Pemafibrate, a selective PPARα modulator, and fenofibrate suppress microglial activation through distinct PPARα and SIRT1-dependent pathways
10.1016/j.bbrc.2020.01.118 · 2020 · External reference
Pemafibrate suppresses oxidative stress and apoptosis under cardiomyocyte ischemia-reperfusion injury in type 1 diabetes mellitus
10.3892/etm.2021.9762 · 2021 · External reference
Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy
10.1038/s41598-022-06542-8 · 2022 · External reference
Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury
10.1371/journal.pone.0241195 · 2020 · External reference
Selective activation of PPARα by pemafibrate mitigates peritoneal inflammation and fibrosis through suppression of NLRP3 inflammasome and modulation of inflammation
10.1038/s41598-024-74340-5 · 2024 · External reference
Hypertriglyceridemia impairs HDL functionality, promotes macrophage metabolic activation and exacerbates antigen-induced rheumatoid arthritis in mice which can be reversed by fenofibrate treatment
10.1016/j.bbalip.2025.159686 · 2025 · External reference
Bezafibrate, a Pan PPAR agonist, attenuates experimental rheumatoid arthritis via PPAR dependent modulation of inflammatory pathways with emphasis on PPAR γ activity
10.1016/j.intimp.2025.115797 · 2026 · External reference
Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats
10.3109/13880209.2015.1125931 · 2016 · External reference
Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis
10.1136/ard.2003.015008 · 2004 · External reference
A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis
10.1007/s10165-009-0261-2 · 2010 · External reference
The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study
10.1007/s00296-012-2613-z · 2013 · External reference
Targeting nuclear hormone receptors: PPARα agonists as potential disease-modifying drugs for rheumatoid arthritis
10.1155/2011/937843 · 2011 · External reference
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
10.1136/ard-2022-223356 · 2023 · External reference
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
10.1002/art.27584 · ExternalCitation · doi-reference
Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors
10.1007/s00011-019-01231-1 · ExternalCitation · doi-reference
The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study
10.1007/s00296-012-2613-z · ExternalCitation · doi-reference
A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis
10.1007/s10165-009-0261-2 · ExternalCitation · doi-reference
Hypertriglyceridemia impairs HDL functionality, promotes macrophage metabolic activation and exacerbates antigen-induced rheumatoid arthritis in mice which can be reversed by fenofibrate treatment
10.1016/j.bbalip.2025.159686 · ExternalCitation · doi-reference
Pemafibrate, a selective PPARα modulator, and fenofibrate suppress microglial activation through distinct PPARα and SIRT1-dependent pathways
10.1016/j.bbrc.2020.01.118 · ExternalCitation · doi-reference
Bezafibrate, a Pan PPAR agonist, attenuates experimental rheumatoid arthritis via PPAR dependent modulation of inflammatory pathways with emphasis on PPAR γ activity
10.1016/j.intimp.2025.115797 · ExternalCitation · doi-reference
Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy
10.1038/s41598-022-06542-8 · ExternalCitation · doi-reference
Selective activation of PPARα by pemafibrate mitigates peritoneal inflammation and fibrosis through suppression of NLRP3 inflammasome and modulation of inflammation
10.1038/s41598-024-74340-5 · ExternalCitation · doi-reference
The pathogenesis of rheumatoid arthritis
10.1056/nejmra1004965 · ExternalCitation · doi-reference
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
10.1136/ard-2022-223356 · ExternalCitation · doi-reference
Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis
10.1136/ard.2003.015008 · ExternalCitation · doi-reference
Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values
10.1136/ard.2006.054205 · ExternalCitation · doi-reference
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
10.1136/ard.2007.084459 · ExternalCitation · doi-reference
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
10.1136/ard.2010.138461 · ExternalCitation · doi-reference
Targeting nuclear hormone receptors: PPARα agonists as potential disease-modifying drugs for rheumatoid arthritis
10.1155/2011/937843 · ExternalCitation · doi-reference
NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction
10.1186/ar300 · ExternalCitation · doi-reference
Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury
10.1371/journal.pone.0241195 · ExternalCitation · doi-reference
Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats
10.3109/13880209.2015.1125931 · ExternalCitation · doi-reference
Pemafibrate suppresses oxidative stress and apoptosis under cardiomyocyte ischemia-reperfusion injury in type 1 diabetes mellitus
10.3892/etm.2021.9762 · ExternalCitation · doi-reference
